Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the ...

Price: KTM 200 Duke price for its variant - 200 Duke Standard starts at Rs. 1,99,100. The mentioned 200 Duke price is the average ex-showroom. KTM 200 Duke is a street bike available in only 1 variant ...

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as longtime rival Dupixent took the crown in September. Sanofi and Regeneron ...

We recently made a list of Morgan Stanley’s Best Overweight & Quality Stocks: Top 25 Stocks. In this piece, we will look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks on the list of the ...

The new Intel Core Ultra 200 series "Arrow Lake-S" desktop CPUs arrive with a new LGA 1851 socket, an entire new fleet of 800-series motherboards led by the Z890 flagship, DDR5 only, and TSMC's ...

The recent FDA approval of Dupixent for treating COPD with eosinophilic phenotype reduces the risk associated with developing APG808, as it targets a similar patient group, highlighting the ...

The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease ...

Oct. 2, 2024 — The FDA has approved Regeneron and Sanofi’s drug Dupixent for patients with COPD (chronic obstructive pulmonary disease). Marking the sixth indication for the drug, the approval ...

TUESDAY, Oct. 1, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic ...

If that describes you, read on for our top recommended cards with signup bonuses of at least $200. You really can’t go wrong with any of these cards, but what you’ll want to pay attention to aside ...

The Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD ...